Abstract: Pharmaceutical compositions comprise as the active ingredient, nonneurotixic antiischemic compounds that are highly effective by the intraperitoneal route, and that are excitatory amino acid and NMDA/sigma receptor antagonists and are selected from the group consisting of those of the formulae, 1

Abstract: Pharmaceutical compositions comprise as the active ingredient, nonneurotixic antiischemic compounds that are highly effective by the intraperitoneal route, and that are excitatory amino acid and NMDA/sigma receptor antagonists and are selected from the group consisting of those of the formulae, wherein R2 is 4-pyridyl, 3-pyridyl, or 2-oxo-1-pyrrolidino and R1 is 3,4- or 3,5-dichloro, p- or m-chloro, p- or m-bromo, p- or m-fluoro, p- or m-trifluoromethyl, p-methyl, p-methoxy, or hydrogen, and those of the formulae, wherein R2 is 4-pyridyl or 3-pyridyl, R3 is hydrogen, methyl or ethyl and R1 is 3,4- or 3,5-dichloro, p- or m-chloro, p- or m-bromo, p- or m-fluoro, p- or m-trifluoromethyl, p-methyl, p-methoxy or hydrogen.

Abstract: Pharmaceutical compositions comprise as the active ingredient, nonneurotixic antiischemic compounds that are highly effective by the intraperitoneal route, and that are excitatory amino acid and NMDA/sigma receptor antagonists and are selected from the group consisting of those of the formulae, 1

Abstract: A specific method of optical resolution using dibenzoyltartrate (DBTA) is described for the preparation of six new (+) and (-) enantiomers each of six racemic aminoalkylpyridines. The (+) enantiomers are potent orally active, non-neurotoxic anticonvulsant compounds that are highly effective in the MES test and the hippocampal kindled rat model with no activity in the sc Met test and that significantly raise seizure threshold in the i.v. Metrazol seizure threshold screen. Pharmaceutical compositions, to treat convulsive disorders, comprising as the active ingredient one of the above (+) or (-) aminoalkylpyridine enantiomers, that are selected from the groups of enantiomers consisting of those of the formulae: ##STR1## wherein R.sup.1 is methyl or ethyl and R.sup.2 is 3,4-dichloro, p- or m-chloro or p-bromo. The compositions are administered to mammals in an amount to provide a dosage amount ranging from about 10 mg/kg to 200 mg/kg of body weight.

Abstract: Pharmaceutical compositions comprise as the active ingredient potent orally active, nonneurotoxic anticonvulsant compounds that are highly effective in the MES animal model and are excitatory amino acid antagonists, and that are selected from the groups of hydrazones, hydrazines and semicarbazones consisting of those of the formulae: ##STR1## wherein R.sup.1 is 4-pyridyl or 3-pyridyl, R.sup.2 is methyl, ethyl or phenyl, R.sup.3 is 3,4-dichloro, p-chloro or m-chloro and R.sup.4 is oxygen. The compositions are administered to mammals in an amount to provide a dosage amount ranging from about 10 mg/kg to 200 mg/kg of body weight.

Abstract: Pharmaceutical compositions comprise as the active ingredient potent orally active, nonneurotoxic anticonvulsant compounds that are excitatory amino acid and NMDA/sigma receptor antagonists and that are selected from the group consisting of those of the formulae: ##STR1## wherein R.sup.1 is 4-pyridyl or 3-pyridyl, R.sup.2 is hydrogen or methyl and R.sup.3 is 3,4-dichloro, p- or m-chloro, p-bromo, p-fluoro, p-methyl, p-methoxy or hydrogen. The compositions are administered to mammals in an amount to provide a dosage amount ranging from about 15 mg/kg to 200 mg/kg.

Abstract: Anticonvulsant compounds are of the formula: ##STR1## wherein R.sup.1 is 2-oxo-1-pyrrolidinyl, and R.sup.2 is hydrogen or p-chloro. They are prepared by the reaction of a phenyl azide with N-vinylpyrrolidinone.

Abstract: Anticonvulsant compositions comprise as the active ingredient a compound selected from the group consisting of those of the formulae: ##STR1## wherein R.sub.1 is o-chlorophenyl, o-nitrophenyl, 2,4- or 2,6-dichlorophenyl, 4-pyridyl, 3-pyridyl, 2-pyridyl, or 2-quinolyl, and R.sub.2 is hydrogen, m- or p-trifluoromethyl, m-chloro-p-fluoro, p-methyl, p-ethyl, m- or p-chloro, m-nitro, p-bromo, p-fluoro, or p-COOR.sub.3, wherein R.sub.3 is lower alkyl of 1 to 4 carbon atoms. The compositions are administered to mammals in an amount to provide a dosage amount ranging from about 30 mg/kg to 300 mg/kg.

Abstract: Anticonvulsant compositions comprise as the active ingredient a compound selected from the group consisting of those of the formulae: ##STR1## wherein R.sub.1 is o-chlorophenyl, o-nitrophenyl, 2,4- or 2,6-dichlorophenyl, 4-pyridyl, 3-pyridyl, 2-pyridyl, or 2-quinolyl, and R.sub.2 is hydrogen, m- or p-trifluoromethyl, m-chloro-p-fluoro, p-methyl, p-ethyl, m- or p-chloro, m-nitro, p-bromo, p-fluoro, or p-COOR.sub.3, wherein R.sub.3 is lower alkyl of 1 to 4 carbon atoms. The compositions are administered to mammals in an amount to provide a dosage amount ranging from about 30 mg/kg to 300 mg/kg.

Abstract: Anticonvulsant compositions comprise as the active ingredient a compound selected from the group consisting of those of the formulae: ##STR1## wherein R.sub.1 is phenyl, 4-pyridyl, 3-pyridyl, or 2-pyridyl, and R.sub.2 is hydrogen, m- or p-methyl, p-methoxy, m- or p-chloro, m- or p-bromo, m- or p-fluoro, m- or p-trifluoromethyl, 3,4-dichloro or 3,5-dichloro. The compositions are administered to mammals in an amount to provide a dosage amount ranging from about 25 mg/kg to 300 mg/kg.

Abstract: Substituted 1,2-diphenylaziridines, particularly those which are substituted by halogen, are useful as pesticidal compositions. These 1,2-diphenylaziridines are of the following formula: ##STR1## wherein X is selected from the group consisting of hydrogen, halogen, and nitro, and Y is selected from the group consisting of hydrogen, halogen, nitro, trifluoromethyl, and lower alkyl of 1-3 carbon atoms, and n is an integer of 1 or 2, provided that when one of X and Y is hydrogen or nitro, the other is halogen.

Abstract: Anticonvulsant compositions comprise as the active ingredient a compound selected from the group consisting of those of the formulae: ##STR1## wherein R.sub.1 is o-chlorophenyl, o-nitrophenyl, 2,4- or 2,6-dichlorophenyl, 4-pyridyl, 2-pyridyl, or 2-quinolyl, and R.sub.2 is hydrogen, m- or p-trifluoromethyl, p-methyl, p-ethyl, m- or p-chloro, m-nitro, p-bromo, p-fluoro or p-COOR.sub.3 wherein R.sub.3 is lower alkyl of 1 to 4 carbon atoms. The compositions are administered to mammals in an amount to provide a dosage amount ranging from about 30 mg/kg to 300 mg/kg.